HBOT Conversations:
Dr. Hemal Mehta & Fasting (Part 2)
Dr. Hemal Mehta, MD is a Medical Director and an Independent Medical Examiner who focuses on pain management through a Regenerative medicine approach. Dr. Mehta is Board Certified in Physical Medicine and Pain Management. He received his Doctor of Medicine Degree from Ross University School of Medicine and completed his residency at East Carolina. He is the Medical Director of Vibrant Health of North Carolina, Tennessee Integrative Pain Institute, and TN Integrative Healthcare: Musculoskeletal and Regenerative Center; additionally, Dr. Mehta is the attending physician at Nashville Regenerative Orthopedics. Dr. Mehta is the 2013 recipient of the Inaugural Patient Appreciation Award at Nashville Academy of Medicine, and the 2004 Research Resident of the Year for East Carolina University. Dr. Mehta has extensive experience with stem cell proliferation, and angiogenesis. He has incorporated Ozone Injection Therapy, PRP (Platelet-Rich Plasma) Injections, Hyperbaric Oxygen Therapy and Regenerative Matrix and Regenerative Medicine Procedures – to name a few – into his integrative wellness & longevity medical practices.
Watch the Podcast
di Girolamo & Dr. Mehta examine the use of Vitamin C IV therapy for cancer, and how the combination of Vitamin C IV therapy, fasting and oxygen therapy – especially in the form of Hyperbaric Oxygen Therapy – has been known to put patients in remission and completely eliminate some very serious cancers. Dr. Mehta describes Hyperbaric Oxygen as a “game changer” when adding it into a cancer treatment protocol. He explains that as doctors they are trained to look at chemotherapy first to treat cancer, but there are many holistic ways to help a cancer patient shrink the tumors, stop the spread and live a longer life. He agrees that HBOT would be a great option to help cancer patients on their healing journey.
Diet is another holistic way to treat cancer. A water fast that puts the body in a ketogenic state, or a ketogenic organic diet are all ranked high as ideal ways to use alternative, natural methods for cancer and pain relief.
Dr. Mehta tells a personal story of his past that involved his father’s diagnosis of papillary thyroid cancer, and how it was the holistic and natural methods Dr. Mehta recommended that gave him extended life. Vitamin C Therapy, consuming organic wheatgrass daily, and daily deep breathing techniques to increase oxygen levels all contributed to him living 3 years longer than his prognosis. After massive shrinkage of the tumors during those 3 years; his father was convinced by an Ocologist to undergo chemotherapy in hopes that it would completely eradicate the cancer from his body. The chemotherapy caused cardio toxicity and unfortunately ultimately lead to Dr. Mehta’s father passing away.
di Girolamo suggests that viewers watch Research Rundown Episode 16: The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer. This is a popular Research Rundown where our host, Ed di Girolamo, analyzes a study led by researcher, Dominic D’Agostino. The benefit of combining ketogenic diet with Hyperbaric Oxygen Therapy (HBOT) for metastatic cancer treatment is some very exciting research in the world of HBOT, cancer research, and fasting! This particular research and Dominic’s involvement to help prove that cancer can be eliminated (and maybe even cured) by combining a heavy ketogenic diet and Hyperbaric Oxygen Therapy is further discussed in this HBOT News Conversations episode with Dr. Mehta.
*Pease consult your doctor to see if fasting is right for you.
Guest

Dr. Hemal Mehta
Subscribe Now, It’s Free!
Recent HBOT News
Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn’s disease.
Fistulizing Crohn’s disease (CD) presents a therapeutic challenge as fistulae are notoriously difficult to heal. Mycobacterium avium ss paratuberculosis (MAP) treatment in CD is gaining attention. We evaluated healing of CD fistula(e) using a novel combination therapy. Nine consecutive patients who failed to heal fistulae on conventional treatment including anti-TNF, were treated with at least three doses of infliximab, 18-30 courses of hyperbaric oxygen therapy and anti-MAP antibiotics comprising rifabutin, clarithromycin and clofazimine. All patients achieved complete healing of fistulae by 6-28 weeks and follow-up for mean 18 months.
Clinical Trial – Dexmedetomidine Versus Magnesium Sulphate for Caesarean Delivery
Regional anesthesia has become more popular in cesarean deliveries because most of the
parturients prefer being awake during the birth process. In addition, regional anesthesia may
be a safer method than general. In spinal anesthesia local anesthetics alone may not be
enough for an effective postoperative analgesia and hemodynamic stability of the patient wich
is crucial during cesarean section. So far many adjuvants have been used to augment the
analgesia produced by intrathecal local anesthetics and to reduce their adverse effects .
Various intrathecal adjuvants to local anaesthetics have found to improve the quality and
extend duration of spinal block. Prolongation of duration of spinal block is desirable both
for long procedures and for postoperative pain relief. Efficacy and safty of intrathecal
magnesium as analgesic adjuvant has been tested by several clinical trails in recent
years.Antinociceptive effect of magnesium appears to be relevant for the management of
chronic and post operative pain. These effects are primarily based on regulation of calcium
influx in to the cell. Magnesium blocks calcium influx and non competitively antagonizes NMDA
channels. NMDA receptor signelling plays an impartent in determining the duration of acute
pain3).) addition of magnesium to spinal anaesthesia improved postoperative analgesia in
orthopedic setting. addition of intrathecal magnesium sulfate to 10 mg bupivacaine plus 25µg
fentanyl prolonged spinal anaesthesia in patients undergoing lower extremity surgery.
Dexmedetomidine is a highly selective 2-adrenergic agonist which has been used as
pre-medication and as an adjuvant to general anesthesia.Dexmedetomidine have several
beneficial actions during perioperative period. They decrease sympathetic tone with
attenuation of the neuroendocrine and haemodynamic response to anaesthesia and surgery,
reduce anaesthetic and opiod requirement, cause sedation and analgesia. Dexmedetomidine was
first introduced into clinical practice as a short term intravenous sedative in intensive
care. Like any other adjuvant dexmedetomidine is not free from adverse effects. Use of
dexmedetomidine is often associated with a decrease in heart rate and blood
pressure.Dexmedetomidine was used to enhance the analgesic property of local anaesthetics
like lidocaine bupivacaine and ropivacaine. In vivo and in vitro studies indicated that these
local anaesthetics had significant neurotoxicity. Dexmedetomidine showed protective or growth
promoting properties in tissues, including nerve cells from cortex. Intrathecal
dexmedetomidine has a neuroprotective effect similar to methylprednisolone.
The mechanism by which intrathecal alpha 2-adrenergic agonists prolong the motor and sensory
block of local anesthetics is not clear. It may be an additive or synergistic effect
secondary to the different mechanisms of action of local anesthetic and alpha 2 adrenergic
agonist. The local anesthetics act by blocking sodium channels, whereas the alpha 2
adrenergic agonist acts by binding to pre synapyic C fibre and post synaptic dorsal horn
neurons. Intrathecal alpha 2 adrenergic agonist produce analgesia by depressing the realease
of C fibre transmission by hyperpolarization of post synaptic dorsal horn neurons. Li et al
observed that Glutamate is involved in excitatory neurotransmission nociception and plays an
essential role in relaying noxious stimuli in the spinal cord. Intrathecal injection of alpha
2 adrenergic agonists produces potent antinociceptive effects by altering spinal
neurotransmitter release and effectively treats acute pain.
Efficacy of hyperbaric oxygen therapy combined with mild hyperthermia for improving the anti-tumour effects of carboplatin.
Abstract: The aim of this study was to evaluate the effects of hyperbaric oxygen therapy (HBO) on the enhancement of hyperthermic chemosensitisation to carboplatin at mild temperatures in experimental tumours. SCCVII carcinoma in C3H/He mice was used to assess tumour...
